Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation
Phase 2
42
about 6.4 years
≤18
1 site in TN
What this study is about
This trial is testing if a treatment using haplo-identical viral-specific T-cells can be safe to treat patients with CMV and ADV after transplant. The goal is to see if this treatment reduces the amount of virus in the blood, making it undetectable.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive VST infusion
- 2.Use CliniMACS
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
infusion
Primary: Degree of reduction of CMV and/or ADV viral load
Secondary: Incidence of AEs related to grade 3-4 cytokine release syndrome (CRS), or grade 1-2 CRS persist beyond 72 hours despite therapy, Incidence of infusion-related grade 3-5 adverse events 24 hours after infusion, Proportion of patients who achieve a negative viral load result at 3 months